Veralipride

Veralipride (Agreal, Agradil) is a typical antipsychotic of the benzamide class. It is indicated for the treatment of vasomotor symptoms associated with menopause. It is a D2 receptor antagonist and it induces prolactin secretion without any estrogenic or progestagenic effects.[1] It was first authorised for use in 1979. Veralipride has never gained approval in the United States.

Veralipride
Ball-and-stick model of the veralipride molecule
Clinical data
Trade namesAgreal, Agradil
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 2,3-dimethoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-5-sulfamoylbenzamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.060.376
Chemical and physical data
FormulaC17H25N3O5S
Molar mass383.46 g·mol−1
3D model (JSmol)
  • COC1=CC(=CC(=C1OC)C(=O)NCC2CCCN2CC=C)S(=O)(=O)N
  • InChI=1S/C17H25N3O5S/c1-4-7-20-8-5-6-12(20)11-19-17(21)14-9-13(26(18,22)23)10-15(24-2)16(14)25-3/h4,9-10,12H,1,5-8,11H2,2-3H3,(H,19,21)(H2,18,22,23) ☒N
  • Key:RYJXBGGBZJGVQF-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

The women who took it, in addition to parkinsonism, were produced by Parkinson's at a very early age, a much more aggressive Parkinson's that progressed much faster and produced death at a very early age. It has also produced other serious effects such as tumors, depression, dementia, etc, etc. For this reason, its sale ceased despite the fact that the Sanofi laboratory knew of the serious side effects it produced and allowed healthy women to continue taking it for years after (even years later its sale was allowed in Mexico after having been banned in all countries for almost 15 years). Europe a medicine that was never approved by the United States)

In September 2006, it was withdrawn from the Spanish market. As a result, the European Commission referred the matter to the European Medicines Agency (EMA). In July 2007, the EMA recommended the withdrawal of marketing authorisations for veralipride.[2]

See also

References
  1. Carranza-Lira S (September 2010). "Actual status of veralipride use". Clinical Interventions in Aging. 5: 271–6. doi:10.2147/cia.s12640. PMC 2938034. PMID 20852674.
  2. "Overall Summary of the Scientific Evaluation of Medicinal Products Containing Veralipride" (PDF). EMEA.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.